Small Stocks, Big Money

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum. The company is strategically prioritizing metastatic breast cancer, where (Z)-endoxifen has shown encouraging clinical activity, favorable tolerability, and potential to address endocrine resistance through dual targeting of ERα and PKCβ1. With multiple Phase 2 trials completed, a proprietary oral formulation, and a strong intellectual property portfolio, Atossa is positioned to deliver meaningful therapeutic innovation and create long-term value for patients and investors alike.Atossa Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/atos to learn more.

Processa Pharmaceuticals (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa's NGC drugs are modifications of existing FDA-approved oncology therapies, resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa's strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.Processa is a client of RedChip. Visit www.redchip.com/stocks/pcsa to learn more.

Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or “over-expressor”) levels.Greenwich LifeSciences is a client of RedChip. Visit RedChip.com/stocks/GLSI to learn more.

Fathom Holdings Inc. (Nasdaq: FTHM) is a technology-driven real estate services platform revolutionizing the traditional brokerage model. Through its innovative flat-fee commission structure, proprietary technology, and integrated offerings—spanning residential brokerage, mortgage, title, and SaaS—Fathom enables agents to maximize their earnings while delivering superior scalability and efficiency. With operations across 43 states and a rapidly growing network of over 14,700 agents, Fathom is well-positioned to capitalize on an improving housing market and expand its disruptive, high-margin approach to real estate services.Visit RedChip.com to learn more.

ASP Isotopes is an advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process, to produce and commercialize highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing.ASP Isotopes is a client of RedChip. Visit www.redchip.com/stocks/aspi to learn more.

Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Osteoarthritis and many other diseases reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”.Enlivex Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/enlv to learn more.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.Visit RedChip.com to learn more.

Foremost Clean Energy Ltd. (Nasdaq: FMST) (CSE: FAT) (WKN: A3DCC8) is a rapidly growing North American uranium and lithium exploration company. The Company holds an option to earn up to a 70% interest in 10 prospective uranium properties (with the exception of the Hatchet Lake, where Foremost is able to earn up to 51%), spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan. As the demand for carbon-free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy. Foremost's uranium projects are at different stages of exploration, from grassroots to those with significant historical exploration and drill-ready targets. The Company's mission is to make significant discoveries alongside and in collaboration with Denison through systematic and disciplined exploration programs.Foremost Clean Energy is a client of RedChip. Visit www.redchip.com/stocks/FMST to learn more.

FatPipe, Inc. (Nasdaq: FATN) is a pioneer in secure, software-defined networking technologies that simplify and fortify enterprise connectivity. The company develops and markets enterprise-class software solutions—including Software-Defined Wide Area Networking (SD-WAN), Secure Access Service Edge (SASE), and Network Monitoring Services (NMS)—that enable customers to unify, secure, and optimize their digital infrastructure across cloud, hybrid, and on-premise environments.FatPipe serves over 2,500 end-user customers worldwide across sectors such as government, healthcare, finance, education, and retail, with its largest customer bases in the U.S. and India. The company’s patented technology allows for intelligent traffic failover, enhanced security, simplified network management, and deep observability—all delivered through a flexible, subscription-based model. For the fiscal year ended March 31, 2024, FatPipe generated $17.9 million in revenue and $4.4 million in net income—reflecting a strong 24.4% net margin.FatPipe is a client of RedChip. Visit RedChip.com to learn more.

BioVie (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.BioVie is a client of RedChip. Visit RedChip.com to learn more.

Liberty Star Minerals (OTCQB: LBSR) is a U.S.-based mineral exploration company focused on advancing high-potential copper and gold projects in Arizona’s premier mining districts. The company’s flagship assets include the Red Rock Canyon Gold Project, a rapidly emerging high-grade epithermal gold discovery, and the Hay Mountain Project, a large-scale copper-gold porphyry target with confirmed mineralization. With recent bonanza-grade gold assays at Red Rock Canyon and first-ever drilling validating Hay Mountain’s porphyry potential, Liberty Star is strategically positioned for significant value creation. The company is actively seeking a joint venture partnership to accelerate development while leveraging strong exploration results and a favorable commodities market.Visit www.redchip.com/stocks/lbsr to learn more.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum. The company is prioritizing metastatic breast cancer, a setting with limited effective therapies and high unmet need, where (Z)-endoxifen has demonstrated encouraging clinical activity and favorable tolerability. This focus may enable a more efficient regulatory pathway while building a foundation for expansion into prevention, neoadjuvant, and adjuvant settings. With multiple ongoing Phase 2 trials, a proprietary oral formulation, and a strong intellectual property portfolio, Atossa is positioned to deliver meaningful therapeutic innovation and create long-term value for patients and investors alike.Visit RedChip.com to learn more.

ConnectM Technology Solutions (Nasdaq: CNTM) is enabling a faster, smarter transition to an all-electric future through its AI-driven energy intelligence platform. The company integrates electrified energy assets with proprietary technology solutions, enabling residential, commercial, and transportation customers to efficiently transition from fossil fuels to renewable energy sources. With 120,000+ connected assets and growing, ConnectM is uniquely positioned in the rapidly expanding $2 trillion electrification market. Operating across Building Electrification, Distributed Energy, and Transportation & Logistics segments, ConnectM provides high-margin, scalable solutions, including AI-powered heat pumps, EV solutions, and smart energy management. Backed by a history of 20 consecutive quarters of revenue growth, a vertically integrated service network, and a first-mover advantage, ConnectM proving that an electrified economy is profitable.ConnectM Technology is a client of RedChip. Visit www.redchip.com/stocks/cntm to learn more.

bioAffinity Technologies (Nasdaq: BIAF) addresses the urgent need for noninvasive, accurate early-stage cancer diagnosis and broad-spectrum cancer treatments. Lung cancer is the leading cause of cancer-related deaths. The Company’s first product, CyPath® Lung, improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. CyPath® Lung, a laboratory developed test (LTD), is patient-friendly and physician focused. Physicians order CyPath® Lung for their patients after lung cancer screening or other imaging reveals a suspicious finding.Patients collect their sample at home and ship overnight in a pre-paid envelope to the Company’s commercial laboratory, Precision Pathology Laboratory Services, where data is collected using flow cytometry. Proprietary automated data analysis, developed using artificial intelligence (AI), detects lung cancer by analyzing the lung microenvironment to identify cell populations that indicate malignancy. CyPath® Lung has shown high sensitivity (92%), high specificity (87%) and high accuracy (88%) in detecting early-stage lung cancer in patients with small pulmonary nodules less than 20 millimeters. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology.bioAffinity is a client of RedChip. Visit www.redchip.com/stocks/BIAF to learn more.

Connect Biopharma Holdings Ltd. (Nasdaq: CNTB) is a clinical-stage biotechnology company advancing innovative therapeutics designed to transform the treatment landscape for inflammatory diseases driven by T-cell dysfunction. The company’s lead candidate, rademikibart, is a next-generation, highly differentiated monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), with potential applications in asthma and chronic obstructive pulmonary disease (COPD)—markets collectively representing multi-billion-dollar commercial opportunities. Backed by robust clinical data from a global Phase 2 study demonstrating superior efficacy, rapid onset of action, and a favorable safety profile, Connect is strategically positioned to enter clinical trials targeting acute exacerbations in respiratory diseases, an area of significant unmet medical need. With a newly strengthened U.S.-based management team experienced in successful drug development and regulatory execution, including having collectively received FDA marketing approval for 16 therapeutic products, and with deep expertise in business development, corporate strategy, finance and operations, Connect Biopharma is uniquely positioned for substantial growth as it moves toward pivotal clinical milestones and commercialization.Connect Biopharma is a client of RedChip. Visit www.redchip.com/stocks/cntb to learn more.

BullFrog AI, a US-company headquartered in Maryland, is revolutionizing drug discovery and development with BullFrog Data Networks®, a cutting-edge platform powered by its proprietary bfLEAP® technology. Designed for small and mid-sized biopharma companies, BullFrog Data Networks® enables users to harness high-dimensional, multi-modal datasets, uncovering hidden relationships and pathways to accelerate target identification, clinical trial optimization, and drug repurposing. By providing affordable, AI-powered insights, BullFrog AI enhances decision-making and efficiency across the industry—helping resource-constrained organizations do more with less while enabling larger enterprises to optimize R&D investments and streamline drug development. In addition to driving growth through its Data Networks platform, BullFrog AI continues to advance its portfolio of licensed drug assets and partnerships with world-class research institutions like the J. Craig Venter Institute and the Lieber Institute for Brain Development.Bullfrog AI is a client of RedChip. Visit RedChip.com/stocks/BFRG to learn more.

Headquartered in Los Angeles, CA, LiveOne (Nasdaq: LVO) is an award-winning, creator-first, music, entertainment, and technology platform focused on delivering premium experiences and content worldwide through memberships and live and virtual events. LiveOne's subsidiaries include Slacker Radio, PodcastOne (Nasdaq: PODC), PPVOne, CPS, LiveXLive, DayOne Music Publishing, Drumify and Splitmind. LiveOne is available on iOS, Android, Roku, Apple TV, Spotify, Samsung, Amazon Fire, Android TV, and through STIRR's OTT applications.LiveOne is a client of RedChip. Visit www.redchip.com/stocks/LVO to learn more.

Nexalin Technology is a pioneering medical technology company focused on addressing the global mental health crisis through innovative neurostimulation devices. Nexalin's products, which include the Gen-2 and newly introduced Gen-3 HALO™ Clarity devices, are non-invasive and utilize advanced frequency-based stimulation to target deep brain structures associated with various mental health disorders. These disorders include but are not limited to depression, anxiety, insomnia, PTSD, and traumatic brain injuries. Nexalin's commitment to non- pharmacological treatment options is underpinned by extensive clinical research and intellectual property protections, aiming to provide significant therapeutic benefits without adverse effects. The company's approach integrates product innovation with a virtual clinic model to enhance accessibility and effectiveness of treatments, offering a significant step forward in mental healthcare.Nexalin Technology is a client of RedChip. Visit RedChip.com to learn more.

Knightscope (Nasdaq: KSCP) is transforming public safety with cutting-edge robotics and AI technologies. From autonomous security robots to advanced detection systems, Knightscope is committed to building safer communities where you live, work, study and visit. Their long-term ambition is bold but simple: to make the United States of America the safest country in the world.Knightscope is a client of RedChip Companies. Visit RedChip.com to learn more.

Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage pharmaceutical company pioneering treatments for neuroinflammation and rare diseases through its proprietary resveratrol delivery platform. Its lead product, JOTROL™, offers groundbreaking bioavailability—nine times greater than traditional resveratrol formulations—enabling safe, effective treatment for CNS disorders like Alzheimer's and Parkinson's. Backed by elite research partnerships and a robust clinical pipeline, including multiple Phase 2 trials expected to launch within the next 12 months, Jupiter is also advancing a near-term direct-to-consumer revenue opportunity in nutraceuticals, positioning the company as a transformative force in both pharmaceutical and consumer health markets.Jupiter Neurosciences is a client of RedChip. Visit www.redchip.com/stocks/JUNS to learn more.